<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197910</url>
  </required_header>
  <id_info>
    <org_study_id>BACCHUS_PASTATREND_2014</org_study_id>
    <nct_id>NCT02197910</nct_id>
  </id_info>
  <brief_title>Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects</brief_title>
  <official_title>Association Between Consumption of Different Dosages of Bioactive Wheat Peptides and Blood Pressure (BP) Level and Other Biomarkers of Cardiovascular Disease Risk in Healthy Subjects With High-normal BP: a Double-blind, Cross-over, RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we will assess the effects of bioactive peptide rich wheat products on blood&#xD;
      pressure and estimated cardiovascular disease risk. This will be a pilot, explorative,&#xD;
      cross-over, randomized double-blind 2 groups x 2-arms controlled, clinical trial. The&#xD;
      intervention will be based on commercially-packaged pasta, which will appear and taste the&#xD;
      same; (i) low dose bioactive peptides vs. (ii) high dose bioactive peptides. Inclusion&#xD;
      Criteria will be: Male and female non-diabetic adult volunteers at increased estimated CV&#xD;
      risk (ESC/EAS SCORE) with SBP 130-139 mmHg and/or DBP 85-90 mmHg); Age included between 40&#xD;
      and 70 years old; Primary prevention for CVD but otherwise in good general health and have&#xD;
      had no major illness in the previous 6-months; Volunteer providing their signed and dated&#xD;
      informed consent form. Exclusion Criteria will be: Severe medical illness/chronic&#xD;
      disease/gastrointestinal pathology (e.g. coeliac disease); Secondary prevention for CVD;&#xD;
      Treatment with drugs potentially affecting BP (including antihypertensive drugs) or other&#xD;
      related CV risk factors; Consumption of nutraceuticals, botanical extracts or other vitamin&#xD;
      supplements; Volunteer diagnosed as being hypertensive A total of 60 participants will be&#xD;
      recruited and following adherence to a standardized diet for a 4-week period, will be&#xD;
      randomly assigned to complete one of 2 treatment sequences by consuming a prescribed quantity&#xD;
      of pasta products for a 4-week period followed by a 4-week washout before random assignment&#xD;
      to the 2nd treatment.&#xD;
&#xD;
      The Primary Outcome will be the modification of office blood pressure (assessed by systolic&#xD;
      and diastolic BP, pulse and mean pressure (mean of 3 standing &amp; sitting measures) and 24-hour&#xD;
      blood pressure.&#xD;
&#xD;
      Additional outcomes include: Anthropometric parameters (Weight, WC, HC, WC/HC, ICO, BMI),&#xD;
      Glucose and Lipid profile (TC, LDL-C, HDL-C, TG, non-HDL cholesterol, risk ratios), Estimated&#xD;
      CVD risk changes (EAS/ESC SCORE Charts), Measures of vascular health (FMD, PWA, PWV, Aix),&#xD;
      Liver and renal functionality biomarkers, 24-h urine collection at baseline of treatment&#xD;
      phase 1 and endpoint of the final phase will be analysed to account for potential confounding&#xD;
      of urinary sodium excretion (intake) As required by the GCPs and GLPs, all the SOPs have&#xD;
      already been established and all the personnel to be involved in the study is continuously&#xD;
      trained in trials with similar outcomes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Office blood pressure modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>Systolic, diastolic, pulse, mean arterial pressure, pulse pressure index, mean of 3 consecutive measurement as for the European guidelines on blood pressure measurement suggestion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour blood pressure modification (ABPM)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Twenty-four hour ambulatory blood pressure monitoring (ABPM) will be performed using a non-invasive automatic monitor (Space Labs, model 90207). For ABPM, patients will be instructed to act and work as normal between 6:00 AM and 10:00 PM and rest or sleep between 10:00 PM and 6:00 AM. Readings were obtained automatically at 15-min intervals throughout a 24-h study period. Separate averages will be obtained for the 24-h, daytime (6:00 AM-10:00 PM) and night-time (10:00 PM-6:00 AM) values. The accuracy of the automatic blood pressure readings will be checked against manual readings taken using a standard mercury sphygmomanometer, twice for each ABPM. Blood pressure were was measured with the patient sitting, before the beginning of the ABPM, and after a 5-min rest period. The accuracy test will be repeated after the end of each 24-h ABPM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterolemia modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>12-hour fasting Total, LDL, HDL and non HDL-Cholesterol, evaluated with standardized methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated vasodilation modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluation of endothelial function by automatic measurement executed with the Vicorder Endopath instrument, already validated in previous publications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>12-hour fasting plasma glucose evaluated with standardized methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluation of arterial stiffness measured as Pulse Wave Velocity and related parameters by the Vicorder instrument, already validated in previous publications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceridemia modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>12-hour fasting triglyceridemia evaluated by standardized lab methos</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anthropometric measurement changes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Height, weight, body mass index, waist circumference, hip circumference, waist/hip ratio, visceral adiposity index, index of central obesity measured from trained personnel following SOPs</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver parameters modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>12-hour liver transaminases, gamma-glutamyl-transferase, Lipid Accumulation Product, and Hepatic Steatosis Index evaluated with standardized methods</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function parameter modification</measure>
    <time_frame>4 weeks</time_frame>
    <description>12-hour fasting serum uric acid, creatinine, and estimated glomerular filtration rate (CKD-EPI formula) evaluated with standardized methods</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pre-hypertension</condition>
  <arm_group>
    <arm_group_label>High content of wheat bioactive peptides</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose of wheat bioactive peptides</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 gr pasta/day, containing around 3 mg bioactive peptides</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low-&gt;High)</intervention_name>
    <arm_group_label>Low dose of wheat bioactive peptides</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High-&gt;Low)</intervention_name>
    <arm_group_label>High content of wheat bioactive peptides</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary prevention for cardiovascular diseases&#xD;
&#xD;
          -  Systolic blood pressure 130-139 mmHg and/or Diastolic blood pressure 85-89 mmHg&#xD;
&#xD;
          -  Estimated cardiovascular risk &gt;5% (Italian Heart Project cards)&#xD;
&#xD;
          -  Ability of the volunteer to understand the study finalities and to adhere to the study&#xD;
             protocol&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secundary prevention for cardiovascular disease or high risk to develop cardiovascular&#xD;
             disease&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  High level of a single cardiovascular disease risk factor (i.e.: severe&#xD;
             hypertension/hypercholesterolemia)&#xD;
&#xD;
          -  Chronic renal or liver failure&#xD;
&#xD;
          -  Obesity (Body Mass Index&gt;30 kg/m2)&#xD;
&#xD;
          -  Coeliac disease or gluten intolerance&#xD;
&#xD;
          -  Assumption of antihypertensive drugs at antihypertensive dosageâ€¢ Each medical or&#xD;
             surgery condition potentially making difficult or inconstant the volunteer adhesion to&#xD;
             the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Borghi, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Borghi, MD</last_name>
    <email>claudio.borghi@unibo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arrigo FG Cicero, MD, PhD</last_name>
    <email>arrigo.cicero@unibo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S. Orsola-Malpighi University Hospital</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arrigo FG Cicero, MD, PhD</last_name>
      <phone>++39516362224</phone>
      <email>arrigo.cicero@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Arrigo FG Cicero, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Borghi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maddalena Veronesi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio D'Addato, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 19, 2014</study_first_submitted>
  <study_first_submitted_qc>July 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bologna</investigator_affiliation>
    <investigator_full_name>Claudio Borghi</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 7, 2017</submitted>
    <returned>March 27, 2017</returned>
    <submitted>March 30, 2017</submitted>
    <returned>June 19, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

